2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

By sjmartinez • October 30, 2024

Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093/cid/ciae435. Epub ahead of print. PMID: 39471458.

Tags: covid-19, guideline, Infectious Diseases, pemivibart, Pre-exposure prophylaxis, Publications, SARS-CoV-2

Detection of Marburg Virus Antibodies 25 Years After Outbreak in Watsa, Democratic Republic of the Congo

Merritt S, Mukadi PK, Kompany JP, Halbrook M, Musene K, Martin SA, Beya M, Tambu M, Wong TAS, Muyembe-Tamfum JJ, Kaba DK, Lehrer AT, Kindrachuk[...]

Navigating Masculinities: An Exploration of Peer Coaching, Health Behaviors, and Mortality Risks Among Men in Tuberculosis and HIV Interventions in South Africa

Rutt K, DeVos L, Gala K, Njama T, Fosi M, Mhaleni Z, Daniels J, Medina-Marino A. Navigating Masculinities: An Exploration of Peer Coaching, Health Behaviors,[...]

Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study

Landovitz RJ, Pinedo Y, Hinestrosa F, Crofoot GE, Brinson C, Buchbinder S, Molina JM, Gravett RM, Brock JB, Ramgopal MN, Rosengren AL, Ofotokun I, Valdez[...]